Published on in Vol 6, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34248, first published .
The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

Journals

  1. Röth A, Broome C, Barcellini W, Jilma B, Hill Q, Cella D, Tvedt T, Yamaguchi M, Lee M, Shafer F, Wardęcki M, Jiang X, Patel P, Joly F, Weitz I. Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study. European Journal of Haematology 2023;110(3):280 View
  2. Röth A, Broome C, Barcellini W, Tvedt T, Miyakawa Y, D’Sa S, Cella D, Bozzi S, Jayawardene D, Yoo R, Shafer F, Wardęcki M, Weitz I. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Advances 2023;7(19):5890 View
  3. Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal of Hematology 2024 View
  4. Jalink M, Jacobs C, Khwaja J, Evers D, Bruggeman C, Fattizzo B, Michel M, Crickx E, Hill Q, Jaeger U, Kater A, Mäkelburg A, Breedijk A, te Boekhorst P, Hoeks M, de Haas M, D’Sa S, Vos J. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Advances 2024;8(11):2622 View

Books/Policy Documents

  1. Bashir S, Chew A. Rook's Textbook of Dermatology. View